Jean‐Jacques Grob
Aix-Marseille Université · 952 works · 94,077 citations · h-index 114
Top works
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study